The French drug maker has raced up the rankings over the last decade largely through M&A activity, with the $20bn purchase this year of US biotechnology specialist Genzyme predicted to help win its number one ranking.
“The takeover of Genzyme, an aggressive cross-border move, revealed just how much the culture of Sanofi has changed in the last few years,” commented Dr Jonathan de Pass, chief executive of EvaluatePharma. “Coming just as Pfizer loses Lipitor, the acquisition should be enough to secure Sanofi the top spot for the next few years, our data suggest.”
For more in-depth analysis and commentary on this news please visit EP Vantage.
“The takeover of Genzyme, an aggressive cross-border move, revealed just how much the culture of Sanofi has changed in the last few years,” commented Dr Jonathan de Pass, chief executive of EvaluatePharma. “Coming just as Pfizer loses Lipitor, the acquisition should be enough to secure Sanofi the top spot for the next few years, our data suggest.”
For more in-depth analysis and commentary on this news please visit EP Vantage.
Companies in this article
